Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Expression of Cell Cycle Biomarkers and Telomere Length in Papillary Thyroid Carcinoma: A Comparative Study Between Radiation-Associated and Spontaneous Cancers

Achille, Mihaela, MD*†; Boukheris, Houda, MD; Caillou, Bernard, MD§; Talbot, Monique, MD§; de Vathaire, Florent, PhD; Sabatier, Laure, PhD*; Desmaze, Chantal, PhD*; Schlumberger, Martin, MD, PhD; Soria, Jean-Charles, MD, PhD*†

American Journal of Clinical Oncology: February 2009 - Volume 32 - Issue 1 - p 1-8
doi: 10.1097/COC.0b013e3181783336
Original Article: Endocrine

Objective: Radiation exposure during childhood is the only well-established risk factor for papillary thyroid carcinoma (PTC). To better define the biologic profile of radiation-induced and sporadic PTC, we compared in these two groups of PTC the expression of cell cycle regulatory proteins and telomere length.

Methods: Cell cycle markers (cyclin A, B1, D1, E, and Ki67) were evaluated on 100 PTC specimens (26 radiation-induced and 74 sporadic PTCs). The expression of cell cycle regulators was studied using immunohistochemistry; telomere length heterogeneity was studied using in situ hybridization in a subset of 16 formalin-fixed samples (8 radiation-induced and 8 sporadic PTCs).

Results: At multivariate analysis, only cytoplasmic cyclin E staining was overexpressed in sporadic cases (P = 0.006). The other cell cycle markers and telomere length did not differ significantly between sporadic PTC and radiation-induced PTC.

Conclusions: These markers cannot be used to differentiate radiation-induced from sporadic PTCs.

From the *Laboratoire de Radiobiologie et Oncologie, DSV/DRR/Commissariat à l’Energie Atomique, Villejuif, France; Departments of †Medicine, §Biopathology, and ¶Nuclear Medicine, Institut Gustave Roussy, Villejuif, France; and ‡Unit 605, National Institute of Health and Medical Research (INSERM), Institute Gustave Roussy, University Paris XI, Villejuif, France.

Supported by a grant from Institute Gustave Roussy in the frame of the Diplôme Universitaire Européen de Recherche en Cancérologie Clinique (to M.A). This study was also supported in part by a grant from Electricité de France (to J.C.S.). H. Boukheris received a fellowship from the International Agency for Research on Cancer.

Reprints: Jean Charles Soria, MD, PhD, Department of Medicine, Institute Gustave Roussy, 94805 Villejuif, Cédex, France. E-mail:

© 2009 Lippincott Williams & Wilkins, Inc.